(Q37664335)

21 August 2017

1 reference

title

Integrase inhibitors: a novel class of antiretroviral agents (English)

1 reference

21 August 2017

main subject

anti-retroviral agent

0 references

elvitegravir

1 reference

ChEBI release 2020-05-28

Jason J Schafer

1

1 reference

21 August 2017

Kathleen E Squires

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

29 December 2009

1 reference

Annals of Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

44

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

145-156

1 reference

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

21 August 2017

cites work

1 reference

Integrase inhibitors to treat HIV/AIDS.

21 January 2018

1 reference

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

Emerging pharmacology: inhibitors of human immunodeficiency virus integration

21 January 2018

1 reference

Structure and function of HIV-1 integrase

21 January 2018

1 reference

Repair of gaps in retroviral DNA integration intermediates

21 January 2018

1 reference

Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection

21 January 2018

1 reference

Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

21 January 2018

1 reference

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

Decay characteristics of HIV-1-infected compartments during combination therapy

21 January 2018

1 reference

Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals

21 January 2018

1 reference

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

21 January 2018

1 reference

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms

21 January 2018

1 reference

Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation

21 January 2018

1 reference

Effects of omeprazole on plasma levels of raltegravir

21 January 2018

1 reference

Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir

21 January 2018

1 reference

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects

21 January 2018

1 reference

Lack of a significant drug interaction between raltegravir and tenofovir.

21 January 2018

1 reference

Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases

21 January 2018

1 reference

Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics

21 January 2018

1 reference

Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure

21 January 2018

1 reference

Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir

21 January 2018

1 reference

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

21 January 2018

1 reference

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

21 January 2018

1 reference

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen

21 January 2018

1 reference

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

21 January 2018

1 reference

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1M309

1 reference

21 August 2017

1 reference